Intravenous mitoxantrone and cyclophosphamide as second-line therapy in multiple sclerosis: An open-label comparative study of efficacy and safety

Journal of the Neurological Sciences

Volumn 266, Issue 1-2, 2008, Pages 25-30

  Zipoli, Valentina ^a   Portaccio, Emilio ^a   Hakiki, Bahia ^a   Siracusa, Gianfranco ^a   Sorbi, Sandro ^a   Pia Amato, Maria ^a  

^a UNIVERSITY OF FLORENCE   (Italy)

Author keywords

Comparative study; Cyclophosphamide; Mitoxantrone; Multiple sclerosis

Indexed keywords

CYCLOPHOSPHAMIDE; MITOXANTRONE; ONDANSETRON;

ADULT; ALOPECIA; AMENORRHEA; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE COURSE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EXPANDED DISABILITY STATUS SCALE; FEMALE; FOLLOW UP; HEMATURIA; HUMAN; IMMUNOGLOBULIN DEFICIENCY; KAPLAN MEIER METHOD; MAJOR CLINICAL STUDY; MALE; MULTIPLE SCLEROSIS; MYELODEPRESSION; NAUSEA; NAUSEA AND VOMITING; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; RELAPSE; RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION; VOMITING;

ADULT; ALKYLATING AGENTS; ANTINEOPLASTIC AGENTS; BLOOD CELL COUNT; CYCLOPHOSPHAMIDE; DISEASE PROGRESSION; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; HUMANS; INJECTIONS, INTRAVENOUS; MAGNETIC RESONANCE IMAGING; MALE; MITOXANTRONE; MULTIPLE SCLEROSIS; MULTIPLE SCLEROSIS, CHRONIC PROGRESSIVE; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; QUALITY OF LIFE; REGRESSION ANALYSIS; TREATMENT OUTCOME;

EID: 38749104248     PISSN: 0022510X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jns.2007.08.023     Document Type: Article

References (34)

1. Steinman L. Multiple sclerosis: a coordinated immunological attack against myelin in the central nervous system. Cell 85 3 (May 3 1996) 299-302
2. Martin R., McFarland H.F., and McFarlin D.E. Immunological aspects of demyelinating diseases. Annu Rev Immunol 10 (1992) 153-187
3. Hafler D.A., and Weiner H.L. Immunologic mechanisms and therapy in multiple sclerosis. Immunol Rev 144 (Apr 1995) 75-107
4. Edan G., Miller D., Clanet M., Confavreux C., Lyon-Caen O., Lubetzki C., et al. Therapeutic effect of mitoxantrone combined with methylprednisolone in multiple sclerosis: a randomised multicentre study of active disease using MRI and clinical criteria. J Neurol Neurosurg Psychiatry 62 2 (Feb 1997) 112-118
5. Hartung H.P., Gonsette R., Konig N., Kwiecinski H., Guseo A., Morrissey S.P., et al. Mitoxantrone in progressive multiple sclerosis: a placebo-controlled, double-blind, randomised, multicentre trial. Lancet 360 9350 (Dec 21-28 2002) 2018-2025
6. Millefiorini E., Gasperini C., Pozzilli C., D'Andrea F., Bastianello S., Trojano M., et al. Randomized placebo-controlled trial of mitoxantrone in relapsing-remitting multiple sclerosis: 24-month clinical and MRI outcome. J Neurol 244 3 (Mar 1997) 153-159
7. Scott L.J., and Figgitt D.P. Mitoxantrone: a review of its use in multiple sclerosis. CNS Drugs 18 6 (2004) 379-396
8. Goodin D.S., Frohman E.M., Garmany Jr. G.P., Halper J., Likosky W.H., Lublin F.D., et al. Disease modifying therapies in multiple sclerosis: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and the MS Council for Clinical Practice Guidelines. Neurology 58 2 (Jan 22 2002) 169-178
9. Martinelli Boneschi F., Rovaris M., Capra R., and Comi G. Mitoxantrone for multiple sclerosis. Cochrane Database Syst Rev 4 (2005) CD002127
10. Gourley M.F., Austin III H.A., Scott D., Yarboro C.H., Vaughan E.M., Muir J., et al. Methylprednisolone and cyclophosphamide, alone or in combination, in patients with lupus nephritis. A randomized, controlled trial. Ann Intern Med 125 7 (Oct 1 1996) 549-557
11. TCCMSS Group. The Canadian cooperative trial of cyclophosphamide and plasma exchange in progressive multiple sclerosis. Lancet 337 8739 (1991 Feb 23) 441-446
12. Hommes O.R., Prick J.J., and Lamers K.J. Treatment of the chronic progressive form of multiple sclerosis with a combination of cyclophosphamide and prednisone. Clin Neurol Neurosurg 78 1 (1975) 59-72
13. Carter J.L., Hafler D.A., Dawson D.M., Orav J., and Weiner H.L. Immunosuppression with high-dose i.v. cyclophosphamide and ACTH in progressive multiple sclerosis: cumulative 6-year experience in 164 patients. Neurology 38 7 Suppl 2 (Jul 1988) 9-14
14. Gonsette R.E., Demonty L., and Delmotte P. Intensive immunosuppression with cyclophosphamide in multiple sclerosis. Follow up of 110 patients for 2-6 years. J Neurol 214 3 (Feb 17 1977) 173-181
15. Hauser S.L., Dawson D.M., Lehrich J.R., Beal M.F., Kevy S.V., Propper R.D., et al. Intensive immunosuppression in progressive multiple sclerosis. A randomized, three-arm study of high-dose intravenous cyclophosphamide, plasma exchange, and ACTH. N Engl J Med 308 4 (Jan 27 1983) 173-180
16. Theys P., Gosseye-Lissoir F., Ketelaer P., and Carton H. Short-term intensive cyclophosphamide treatment in multiple sclerosis. A retrospective controlled study. J Neurol 225 2 (1981) 119-133
17. Likosky W.H., Fireman B., Elmore R., Eno G., Gale K., Goode G.B., et al. Intense immunosuppression in chronic progressive multiple sclerosis: the Kaiser study. J Neurol Neurosurg Psychiatry 54 12 (Dec 1991) 1055-1060
18. La Mantia L., Milanese C., Mascoli N., Incorvaia B., D'Amico R., and Weinstock-Guttman B. Cyclophosphamide for multiple sclerosis. Cochrane Database Syst Rev 4 (2002) CD002819
19. Portaccio E., Zipoli V., Siracusa G., Piacentini S., Sorbi S., and Amato M.P. Safety and tolerability of cyclophosphamide 'pulses' in multiple sclerosis: a prospective study in a clinical cohort. Mult Scler 9 5 (Oct 2003) 446-450
20. Perini P., Calabrese M., Tiberio M., Ranzato F., Battistin L., and Gallo P. Mitoxantrone versus cyclophosphamide in secondary-progressive multiple sclerosis: a comparative study. J Neurol (Apr 11 2006)
21. Caon C., Din M., Madak S., Tselis A., Lisak R., and Khan O. Two year open-label observational study comparing monthly intravenous cyclophosphamide and every three month IV mitoxantrone in worsening MS patients. Neurology 64 Suppl 1 (2005) A329-A330
22. McDonald W.I., Compston A., Edan G., Goodkin D., Hartung H.P., Lublin F.D., et al. Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann Neurol 50 1 (2001 Jul) 121-127
23. Polman C.H., Reingold S.C., Edan G., Filippi M., Hartung H.P., Kappos L., et al. Diagnostic criteria for multiple sclerosis: 2005 revisions to the "McDonald Criteria". Ann Neurol 58 6 (2005 Dec) 840-846
24. Kurtzke J.F. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 33 11 (Nov 1983) 1444-1452
25. Rieckmann P., Toyka K.V., Bassetti C., Beer K., Beer S., Buettner U., et al. Escalating immunotherapy of multiple sclerosis-new aspects and practical application. J Neurol 251 11 (Nov 2004) 1329-1339
26. Khan O.A., Zvartau-Hind M., Caon C., Din M.U., Cochran M., Lisak D., et al. Effect of monthly intravenous cyclophosphamide in rapidly deteriorating multiple sclerosis patients resistant to conventional therapy. Mult Scler 7 3 (Jun 2001) 185-188
27. Hohol M.J., Olek M.J., Orav E.J., Stazzone L., Hafler D.A., Khoury S.J., et al. Treatment of progressive multiple sclerosis with pulse cyclophosphamide/methylprednisolone: response to therapy is linked to the duration of progressive disease. Mult Scler 5 6 (Dec 1999) 403-409
28. Gobbini M.I., Smith M.E., Richert N.D., Frank J.A., and McFarland H.F. Effect of open label pulse cyclophosphamide therapy on MRI measures of disease activity in five patients with refractory relapsing-remitting multiple sclerosis. J Neuroimmunol 99 1 (Sep 1 1999) 142-149
29. Jeffery D.R., Absher J., Pfeiffer F.E., and Jackson H. Cortical deficits in multiple sclerosis on the basis of subcortical lesions. Mult Scler 6 1 (2000 Feb) 50-55
30. Weinshenker B.G., Rice G.P., Noseworthy J.H., Carriere W., Baskerville J., and Ebers G.C. The natural history of multiple sclerosis: a geographically based study. 4. Applications to planning and interpretation of clinical therapeutic trials. Brain 114 Pt 2 (Apr 1991) 1057-1067
31. Ghalie R.G., Mauch E., Edan G., Hartung H.P., Gonsette R.E., Eisenmann S., et al. A study of therapy-related acute leukaemia after mitoxantrone therapy for multiple sclerosis. Mult Scler 8 5 (Oct 2002) 441-445
32. Talar-Williams C., Hijazi Y.M., Walther M.M., Linehan W.M., Hallahan C.W., Lubensky I., et al. Cyclophosphamide-induced cystitis and bladder cancer in patients with Wegener granulomatosis. Ann Intern Med 124 5 (Mar 1 1996) 477-484
33. Moore M.J. Clinical pharmacokinetics of cyclophosphamide. Clin Pharmacokinet 20 3 (Mar 1991) 194-208
34. Radis C.D., Kahl L.E., Baker G.L., Wasko M.C., Cash J.M., Gallatin A., et al. Effects of cyclophosphamide on the development of malignancy and on long-term survival of patients with rheumatoid arthritis. A 20-year followup study. Arthritis Rheum 38 8 (Aug 1995) 1120-1127